Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Expected to Announce Quarterly Sales of $25.47 Million

Brokerages forecast that Xeris Biopharma Holdings, Inc. (NASDAQ:XERSGet Rating) will report sales of $25.47 million for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Xeris Biopharma’s earnings. The lowest sales estimate is $24.69 million and the highest is $27.20 million. Xeris Biopharma posted sales of $8.84 million during the same quarter last year, which would indicate a positive year over year growth rate of 188.1%. The firm is scheduled to announce its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Xeris Biopharma will report full year sales of $109.97 million for the current fiscal year, with estimates ranging from $103.00 million to $117.90 million. For the next fiscal year, analysts forecast that the business will post sales of $158.63 million, with estimates ranging from $136.00 million to $192.40 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow Xeris Biopharma.

Xeris Biopharma (NASDAQ:XERSGet Rating) last issued its earnings results on Thursday, March 10th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.21). Xeris Biopharma had a negative return on equity of 258.57% and a negative net margin of 217.81%. The business had revenue of $21.43 million during the quarter, compared to analysts’ expectations of $20.72 million. During the same period last year, the firm posted ($0.41) EPS.

Several analysts have commented on XERS shares. Craig Hallum assumed coverage on shares of Xeris Biopharma in a research report on Thursday, April 28th. They set a “buy” rating and a $6.50 price target for the company. SVB Leerink decreased their target price on Xeris Biopharma from $8.00 to $6.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 16th. Zacks Investment Research raised Xeris Biopharma from a “sell” rating to a “hold” rating in a report on Thursday, May 19th. HC Wainwright reissued a “buy” rating and set a $6.00 target price (down previously from $8.00) on shares of Xeris Biopharma in a research note on Friday, March 11th. Finally, Mizuho cut their price target on shares of Xeris Biopharma from $8.00 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday, March 16th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $6.13.

In other news, insider Paul R. Edick purchased 100,000 shares of the stock in a transaction dated Thursday, May 12th. The shares were bought at an average cost of $1.40 per share, for a total transaction of $140,000.00. Following the transaction, the insider now owns 1,508,064 shares in the company, valued at $2,111,289.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 4.01% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Virtu Financial LLC acquired a new stake in shares of Xeris Biopharma in the first quarter worth $131,000. Royal Bank of Canada lifted its stake in Xeris Biopharma by 115.9% during the first quarter. Royal Bank of Canada now owns 43,405 shares of the company’s stock worth $111,000 after purchasing an additional 23,305 shares during the period. Shay Capital LLC bought a new position in shares of Xeris Biopharma during the 1st quarter worth approximately $34,000. Goldman Sachs Group Inc. lifted its holdings in Xeris Biopharma by 218.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 725,255 shares of the company’s stock valued at $1,857,000 after purchasing an additional 497,564 shares during the last quarter. Finally, State Street Corp raised its stake in shares of Xeris Biopharma by 5.0% in the first quarter. State Street Corp now owns 384,761 shares of the company’s stock valued at $985,000 after acquiring an additional 18,252 shares during the last quarter. 18.72% of the stock is currently owned by institutional investors and hedge funds.

XERS stock opened at $2.08 on Tuesday. Xeris Biopharma has a one year low of $1.25 and a one year high of $4.98. The company has a debt-to-equity ratio of 1.43, a quick ratio of 2.42 and a current ratio of 2.67. The company’s fifty day moving average price is $2.28 and its 200-day moving average price is $2.34. The company has a market capitalization of $138.31 million and a PE ratio of -1.41.

Xeris Biopharma Company Profile (Get Rating)

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.

Recommended Stories

Get a free copy of the Zacks research report on Xeris Biopharma (XERS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Xeris Biopharma (NASDAQ:XERS)

Want More Great Investing Ideas?

Receive News & Ratings for Xeris Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.